Category: Federal Forum Posters
Purpose: Migraine headaches affect up to twelve percent of the population and have been shown to decrease quality of life and work productivity. The primary purpose of our study is to determine the number of patients who should receive prophylactic therapy for migraines based on symptomatology.
Methods: This study will be submitted to the Institutional Review Board for approval. The electronic medical record system will identify patients who are currently receiving abortive therapy medications for migraine headaches. The following data will be collected by the researchers: patient age, gender, ethnicity, comorbid disease states, non-pharmacologic treatment modalities, current medications, length of therapy, frequency of abortive therapy use, vital signs, and other precipitating factors. Results of magnetic resonance imaging (MRI) and computed tomography (CT) will be reviewed if applicable. Provider documentation will be reviewed to determine the indication for prophylactic treatment or documentation contradicting the use of prophylactic treatment. Prophylactic treatment indication will be defined as ≥2 days/week of abortive therapy or ≥ 3 times per month, report of decreased quality of life, acute treatments are ineffective or contraindicated, or prophylactic treatment is requested by the patient. The percentage of patients indicated for prophylactic treatment will be calculated to determine the need for a migraine treatment protocol. All information will be recorded without patient identifiers and will remain in compliance with HIPPA regulations. Pending results of the study, there will be efforts to develop a pharmacist integrated migraine prophylaxis clinic to improve health outcomes for patients.
Results: not applicable
Conclusion: not applicable
Benjamin Miskle– PGY1 Pharmacy Resident, Chillicothe VA Medical Center, Fairborn, OH